drugset / Trial / NCT02559414

Antiplatelet Therapy in HIV

NCT02559414

Phase 2 Completed 55 enrolled NYU Langone Health
RandomizedParallel-groupSingle-blindPrevention

Summary

The proposed study will add to the growing understanding of platelet activity and platelet inhibition in subjects with HIV. It will examine the relationship between platelet activity and its inhibition by antiplatelet therapy (aspirin monotherapy and clopidogrel monotherapy) in this high-risk cohort. Furthermore, it will provide important data on the mechanism of platelet activity and its inhibition using biomarkers of platelet activity, inflammation, immune activity and endothelial function and genetic expression profiling.

Timeline

Start
2015-02
Primary completion
2016-04
Completion
2017-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Aspirin Small molecule 81 mg
Comparator Clopidogrel Small molecule